Subordinate units of the group implement the work in the second half of the year
Release time:
2022-08-04
7# May 11
, Jianfeng Pharmacy held a first-half business analysis meeting. General Manager Xu Junxiong summarized and analyzed the completion of business indicators and work contents in the first half of the year from the aspects of work focus adjustment, store incentive policies, reduction of procurement costs, and training of staff marketing enabling skills. According to the responsibility system requirements of pharmaceutical companies at the beginning of the year, the designated pharmacies of medical insurance were standardized operation, adjusted and improved product structure, to create professional health consultants and other aspects of the second half of the work to make specific arrangements and deployment.7# October 16 , the cable company held a meeting, and the heads of various departments reported on the work in the first half of the year and raised the existing problems. According to the work arrangement of the group's semi-annual meeting, the cable company will focus on the establishment of Zhejiang manufacturing group standards for subway communication cables. Increase the participation of peak brands and further expand the foreign communication cable market; Speed up the technological transformation of equipment and improve the stability of performance indicators of various products; Strengthening production management and improving the qualified rate of products in various processes have arranged and implemented the work in the second half of the year.
7 22 , the pharmaceutical company held a half-year pharmaceutical sales meeting. He Songqin, deputy manager of the sales department of the pharmaceutical company, and Xia Donghua, Zhejiang terminal manager, respectively summarized the work of the pharmaceutical agent and the terminal in the first half of the year and implemented the work arrangement for the second half of the year. Xu Yuting, deputy manager of the sales department, expounded the relevant policies of the current pharmaceutical industry and analyzed the existing problems by means of cases. Zhang Qi, head of the business center of the sales department, introduced the planning of preventing and controlling goods in the first half of the year. At the mid-year meeting of the agency plate, the district managers of Shanghai, Anhui, Jiangsu, Hebei and Hubei shared their work experience in the special period, the quantity of varieties, and the promotion of easy medicine cloud. Jiang Xiaomeng, chairman of the group company and chairman of the pharmaceutical company, and Huang Jinlong, deputy general manager of the group company and general manager of the pharmaceutical company, attended the meeting and put forward specific requirements for the work in the second half of the year. Jiang Xiaomeng stressed that it is necessary to control the fleeing of goods with a zero tolerance attitude, learn to grasp the key points, introduce relevant systems, pay attention to sales risk control, find good agents, and develop sales volume in blank areas. Huang Jinlong analyzed the existing problems from the aspects of marketing team's business level, management system implementation, market development and sales risk. He hoped that the sales department would do a good job in team building, optimize the team structure and strive to improve the team management level. Strengthen market development, help the strong and the weak, and achieve balanced regional development; Continue to explore the innovation of marketing mode and do a good job in academic promotion.
7 23 , Huang Ping Jianfeng Cement Company held a mid-year summary meeting. All departments made detailed reports on the work results, existing problems and work plans for the second half of the year. Huang Ping Jianfeng's management team affirmed the work of various departments in the first half of the year, and put forward suggestions and solutions to the difficulties and problems encountered by various departments. Hu Hongwei, general manager of Huang Ping Jianfeng, stressed that it is necessary to strengthen communication between management, departments and departments, and enhance internal cohesion, so as to promote the better development of enterprises.
(Lang Minxiao Huang Yuan
Ni YingzhenCai Chengbing)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page